Therapy EC and Therapy XT are non-heating infrared lamps and are indicated for adjunctive use in the temporary relief of hand and wrist pain associated with Carpal Tunnel Syndrome.

Device Description

Therapy EC and Therapy XT are made up of ergonomic equipment that is easy to use and operate. They have one infrared laser diode (808nm). Two optical fibers conduct the laser light emitted by each emitter. The optical power emitted is controlled by the electrical current in the laser diodes. Therapy EC and Therapy XT are designed to emit infrared laser light. Additionally, they are intended to be used by health care professionals such as physicians, nurses, and physical therapists, for adjunctive use in the temporary relief of hand of wrist pain associated with Carpal Tunnel Syndrome. Therapy EC and Therapy XT are consisted of components including handpiece holder, battery charging cable, battery, spacer (3 units), safety glasses, eye protector, and transportation case. The only part that touches the patient is the spacer. This component is made of polycarbonate and has the function of creating a safe distance between the Therapy tip and the patient's skin.

AI/ML Overview

The provided FDA 510(k) summary for the "Therapy EC and Therapy XT" infrared lamps does not contain information related to acceptance criteria, device performance, or human subject studies.

The document states that "Substantial equivalence of the subject device to the predicate has been established through the results of nonclinical testing." This means that the FDA cleared the device based on engineering and safety tests, and a comparison to a previously cleared predicate device, rather than explicit clinical efficacy studies for the specific device being submitted.

Therefore, I cannot provide a response to your numbered questions regarding acceptance criteria, study details, human subject data, or ground truth, as this information is not present in the provided text.

The "Non-clinical Performance Testing" section lists various IEC and ISO standards that the device complied with, focusing on laser safety, electrical safety, and software lifecycle processes. These are engineering and quality standards, not clinical performance metrics.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the seal of the Department of Health & Human Services. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square are the words "U.S. FOOD & DRUG" in blue, with the word "ADMINISTRATION" below it.

December 19, 2024

DMC Importacao e Exportacao de Equipamentos LTDA Homero Santiago Antunes and Tatiana Jabor Botura Regulatory Affairs Specialist PR Servicos Regulatorios Administrativos Ltda Rua Alice Alem Saadi, 855/2402 Ribeirao Preto, Sao Paulo 14096570 Brazil

Re: K232813

Trade/Device Name: Therapy EC, Therapy XT Regulation Number: 21 CFR 890.5500 Regulation Name: Infrared Lamp Regulatory Class: Class II Product Code: NHN Dated: November 18, 2024 Received: November 18, 2024

Dear Homero Santiago Antunes and Tatiana Jabor Botura:

We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{1}------------------------------------------------

Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).

Your device is also subject to, among other requirements, the Quality System (OS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.

All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatory

{2}------------------------------------------------

assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Amber T. Ballard -S

Amber Ballard, PhD Assistant Director DHT5B: Division of Neuromodulation and Physical Medicine Devices OHT5: Office of Neurological and Physical Medicine Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

Indications for Use

510(k) Number (if known) K232813

Device Name Therapy EC and Therapy XT

Indications for Use (Describe)

Therapy EC and Therapy XT are non-heating infrared lamps and are indicated for adjunctive use in the temporary relief of hand and wrist pain associated with Carpal Tunnel Syndrome.

Prescription Use (Part 21 CFR 801 Subpart D)

| Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{4}------------------------------------------------

510(k) SUMMARY - K232813

Manufacturer/Submitter:	DMC Importação e Exportação de Equipamentos LTDARua Sebastião de Moraes, 831 - Jardim AlvoradaSão Carlos, SP – BrazilPhone: +55 (16) 2107-2323
Contact:	Homero Santiago Antunes and Tatiana Jabor BoturaRegulatory Affairs SpecialistsPR Serviços Regulatórios Administrativos LtdaPhone: +55 (47) 3804-0075Email: homero@passarini.com.br
Date Prepared:	December 17, 2024
Device Trade Name:	Therapy EC and Therapy XT
Regulation andClassification Description:	21 CFR 890.5500, Infrared lamp
Class:	II
Product Code:	NHN
Predicate Device:	TH0R DDII 830CL3 Laser System (K030226)

Indications for Use

Therapy EC and Therapy XT are non-heating infrared lamps and are indicated for adjunctive use in the temporary relief of hand and wrist pain associated with Carpal Tunnel Syndrome.

Device Description

Therapy EC and Therapy XT are designed to emit infrared laser light. Additionally, they are intended to be used by health care professionals such as physicians, nurses, and physical therapists, for adjunctive use in the temporary relief of hand of wrist pain associated with Carpal Tunnel Syndrome.

Therapy EC and Therapy XT are consisted of components including handpiece holder, battery charging cable, battery, spacer (3 units), safety glasses, eye protector, and transportation case. The only part that touches the patient is the spacer. This component is made of polycarbonate and has the function of creating a safe distance between the Therapy tip and the patient's skin.

{5}------------------------------------------------

Comparison of Technological Characteristics with the Predicate Device

Table 1: Comparison of Subject and Predicate Devices

Contents	Subject device	Primary Predicate
		(K030226)
Device name	Therapy EC and Therapy XT	THOR DDII 830CL3 Laser System
Product code	NHN	NHN
RegulationNumber	21 CFR 890.5500	21 CFR 890.5500
Class	Class II	Class II
Indications foruse	Therapy EC and Therapy XT are non-heating infrared lamps and are indicatedfor adjunctive use in the temporary reliefof hand and wrist pain associated withCarpal Tunnel Syndrome.	The THOR DDII 830CL3 LaserSystem is a non-heating infrared lamp and isindicated for adjunctive use in the temporaryrelief of hand and wrist pain associated withCarpal Tunnel Syndrome.
Operationprinciple	Light emission	Light emission
Emitterstechnology	Diode Laser (Semiconductor)	Diode Laser (Semiconductor)
Optical power	100 mW per emitter	Three 30 mW Gallium Aluminum Arsenide(GaAlAs) laser diodes delivering a totaloutput power of 90 mW
Wavelengths	808 nm	830 nm
Interaction withthe patient	Luminous energy absorption	Luminous energy absorption

The indication for use (IFU) statements of the subject and the predicate devices are identical. The subject and the predicate devices are non-heating infrared laser as defined in 21 CFR 890.5500. Both the subject and the predicate devices use diode lasers to emit photonic energy to tissue. The differences between the subject device and predicate are explained below:

Optical power: According to 60601-2-22 Edition 3.1 2012-10 (Recognition Number 12-268), a tolerance of 20% is accepted, justifying the difference between the subject (100 mW) and the predicate (90 mW) devices.

Wavelength: The absorption coefficient of laser light by melanin, hemoglobin and water at wavelengths 808 and 830 nm are similar.

{6}------------------------------------------------

Non-clinical Performance Testing

The following nonclinical performance testing was conducted to demonstrate substantial equivalence.

IEC 60825-1 Edition 2.0 2007-03 Safety of laser products Part 1: Equipment classification, and . requirements
IEC 60601-1 Edition 3.2 2020-08 Safety requirements for electrical equipment for measurement, control, ● and laboratory use - Part 1: General requirements
IEC 60601-2-22: 2019 Edition 4.0 2019-11 Medical electrical equipment Part 2-22: Particular ● requirements for basic safety and essential performance of surgical, cosmetic, therapeutic and diagnostic laser equipment
IEC 62304:2006+AMD1:2015 Edition 1.1 2015-06 Medical device software Software life cycle processes ●
ISO 10993-1 Fifth edition 2018-08 Biological evaluation of medical devices Part 1: Evaluation and testing . within a risk management process

Clinical Testing

Substantial equivalence of the subject device to the predicate has been established through the results of nonclinical testing.

Conclusion

The Therapy EC and Therapy XT have the same intended use, indications for use, and principles of operation, and highly similar technological characteristics as the predicate device. The technological differences identified do not raise new questions of safety or effectiveness compared to the predicate device. Therefore, the subject device is substantially equivalent to the predicate device.

Regulation Number and Section

§ 890.5500 Infrared lamp.

(a)
Identification. An infrared lamp is a device intended for medical purposes that emits energy at infrared frequencies (approximately 700 nanometers to 50,000 nanometers) to provide topical heating.(b)
Classification. Class II (special controls). The device, when it is an infrared therapeutic heating lamp, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 890.9.